About Humacyte Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://humacyte.com/
Frequently Asked Questions
What is the 52-week range for HUMA?
The 52-week high is $2.55 and the 52-week low is $0.5007.
What is the P/E ratio for HUMA?
The P/E ratio data is currently unavailable.
What is the dividend yield for HUMA?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -516.75%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -4560.82%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 59.62.
Analyst Recommendation Trends
Wall Street analyst consensus for HUMA over the last few months:
Latest HUMA News
Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note
Humacyte, Inc. (HUMA) concluded the recent trading session at $0.5, signifying a -2.86% move from its prior day's close.
Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
DURHAM, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the addition of life science industry veterans Scott Coward and Paul Kuznik to the Company’s Board of Directors, both of whom bring substantial experience in the areas of commercialization, enterprise leadership, and global operations. “We are delighted to welcome two
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
The latest trading day saw Humacyte, Inc. (HUMA) settling at $0.56, representing a -2% change from its previous close.
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know
Humacyte, Inc. (HUMA) reached $0.59 at the closing of the latest trading day, reflecting a +2.23% change compared to its last close.
Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic?
The average brokerage recommendation (ABR) for Humacyte, Inc. (HUMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference
DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY on September 16, 2026, at 11:00am Eastern Time. Management will also b
Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months
– FDA authorizes extension of Symvess expiration dating from 18 months to 36 months – – Extended shelf life supported by additional stability data demonstrating Symvess continues to meet all established quality specifications throughout the 36-month dating period – DURHAM, N.C., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology company that develops bioengineered human tissues, today announced that the U.S. Food and Drug Administration (FDA) has a
Humacyte Receives FDA Authorization To Extend The Expiration Dating Period For Symvess From 18 To 36 Months
Extension for Symvess (acellular tissue engineered vessel-tyod, or ATEV) from 18 months to 36 months when stored refrigerated at 2°C to 8°C (36°F to 46°F).The expiration dating extension is supported by additional
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-14 | Jones Keith Anthony | +10,000 | $0.562 | $5,620 |
| 2026-08-20 | Jones Keith Anthony | +10,000 | $0.693 | $6,930 |
| 2026-08-17 | Jones Keith Anthony | +30,000 | $0.594 | $17,820 |
| 2026-06-11 | Wallace Max N. | +80,000 | - | - |
| 2026-06-11 | Niklason Laura E | +80,000 | - | - |
| 2026-06-11 | Jones Keith Anthony | +80,000 | - | - |
| 2026-06-11 | Green Charles Bruce | +80,000 | - | - |
| 2026-06-11 | Seimetz Diane | +80,000 | - | - |
| 2026-06-11 | Bamforth John Philip | +80,000 | - | - |
| 2026-06-11 | Brown Emery N. | +80,000 | - | - |
| 2026-06-11 | Dougan Brady W | 0 | - | - |
| 2026-06-11 | Constantino Michael T. | +80,000 | - | - |
| 2026-06-11 | Windham-Bannister Susan Richards | +80,000 | - | - |
| 2026-06-11 | Sebelius Kathleen | +80,000 | - | - |
| 2026-05-19 | Sebelius Kathleen | +56,818 | $0.88 | $50,000 |
| 2026-05-18 | Parikh Shamik J | -45,887 | $0.8967 | $41,147 |
| 2026-05-18 | Sander Dale A. | -45,887 | $0.8967 | $41,147 |
| 2026-05-18 | Constantino Michael T. | +11,000 | $0.8945 | $9,840 |
| 2025-11-16 | Sander Dale A. | +311,100 | - | - |
| 2025-11-16 | Parikh Shamik J | +311,100 | - | - |
| 2025-11-16 | Dougan Brady W | +311,100 | - | - |
| 2025-11-16 | Niklason Laura E | +311,100 | - | - |